RxDoctor Payments Data

Bryla Simpson, PA

Medical · San Antonio, TXNPI 1487052379

Payments from drug & device makers

$627in general payments, 2019–2025

Across 23 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$223
  • Lilly USA, LLC$160
  • Bayer$51
  • Revance Therapeutics, Inc.$51
  • Exact Sciences$32
  • Xeris Pharmaceuticals, Inc.$23
  • plus $87 from 6 others

What the payments were for

  • Food & beverage$627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$627 in reported general payments places this provider in the 45th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$9,685
Medicare patients
97
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$36,982
FarxigaDapagliflozin Propanediol20$21,929
TrulicityDulaglutide19$21,365
OzempicSemaglutide21$21,075
JardianceEmpagliflozin13$17,377
Breo ElliptaFluticasone/Vilanterol13$5,853
Rosuvastatin Calcium40$775
Gabapentin44$649
Omeprazole45$637
Atorvastatin Calcium75$575
Fluticasone Propionate37$502
Levothyroxine Sodium60$452
Albuterol Sulfate HfaAlbuterol Sulfate26$437
Lisinopril70$431
Losartan Potassium48$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$160$58,34752 claims
AstraZenecaFarxiga$13$21,92920 claims
Novo NordiskOzempic$14$21,07521 claims
GSKBreo Ellipta$13$5,85313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,490 medical providers in Texas.

Other medical in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →